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We treated patients under age 50 years with iodine-131 (131I)eanti-CD45 antibody combined with ﬂudar-
abine and 2 Gy total body irradiation to create an improved hematopoietic cell transplantation (HCT) strategy
for advanced acute myeloid leukemia or high-risk myelodysplastic syndrome patients. Fifteen patients
received 332 to 1561 mCi of 131I, delivering an average of 27 Gy to bone marrow, 84 Gy to spleen, and 21 Gy to
liver. Although a maximum dose of 28 Gy was delivered to the liver, no dose-limiting toxicity was observed.
Marrow doses were arbitrarily capped at 43 Gy to avoid radiation-induced stromal damage; however, no graft
failure or evidence of stromal damage was observed. Twelve patients (80%) developed grade II graft-versus-
host disease (GVHD), 1 patient developed grade III GVHD, and no patients developed grade IV GVHD during
the ﬁrst 100 days after HCT. Of the 12 patients with chronic GVHD data, 10 developed chronic GVHD, generally
involving the skin and mouth. Six patients (40%) are surviving after a median of 5.0 years (range, 4.2 to
8.3 years). The estimated survival at 1 year was 73% among the 15 treated patients. Eight patients relapsed, 7
of whom subsequently died. The median time to relapse among these 8 patients was 54 days (range, 26 to
1364 days). No cases of nonrelapse mortality were observed in the ﬁrst year after transplantation. However, 2
patients died in remission from complications of chronic GVHD and cardiomyopathy, at 18 months and
14 months after transplantation, respectively. This study suggests that patients may tolerate myeloablative
doses >28 Gy delivered to the liver using 131I-anti-CD45 antibody in addition to standard reduced-intensity
conditioning. Moreover, the arbitrary limit of 43 Gy to the marrow may be unnecessarily conservative, and
continued escalation of targeted radioimmunotherapy doses may be feasible to further reduce relapse.
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Innovative therapeutic approaches are needed to reduce
the morbidity and high relapse rates of patients with
advanced leukemia after myeloablative hematopoietic cell
transplantation (HCT). Increasing radiation or chemotherapydgments on page 1367.
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14.05.014doses of preparative regimens have historically decreased
relapse rates, often at the cost of increased nonrelapse
mortality (NRM) [1,2]. We have developed a strategy using
iodine-131 (131I)elabeled anti-CD45 antibody (BC8) to
deliver targeted hematopoietic irradiation to the bone
marrow, spleen, and lymph nodes in an effort to decrease
relapse without increasing NRM [3-5]. CD45 is a tyrosine
phosphatase stably expressed on virtually all leukocytes at
approximately 200,000 copies/cell and found on approxi-
mately 90% of acute leukemias, but it is absent from non-
hematopoietic tissues [6-10]. Preclinical and clinical studies
have shown that 131I-BC8 Ab can deliver 2 to 3 times moreTransplantation.
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unaffected normal organs, and this targeted, high-dose ra-
diation does not signiﬁcantly increase toxicity when added
to myeloablative conditioning regimens [3,11-13].
Reduced-intensity preparative regimens have been
developed as an alternative approach for older patients and
those with comorbidities that might prevent them from
undergoing a myeloablative HCT procedure. Standard
reduced-intensity regimens, however, have been commonly
associated with higher relapse rates in patients with high
burdens of active leukemia at the time of transplantation. In
view of the minimal added toxicity associated with targeted
radiotherapy, we previously combined 131I-BC8 Ab with a
reduced-intensity conditioning regimen in an effort to
decrease relapse for older patients with advanced myeloid
malignancies [14]. Fifty-eight patients age 50 years or older
with advanced acute myeloid leukemia (AML) (beyond ﬁrst
remission) or high-risk myelodysplastic syndrome (MDS)
(5% marrow blasts at the time of HCT) underwent trans-
plantation after delivery of 131I-BC8 Ab in conjunction with
90 mg/m2 of ﬂudarabine (FLU) and 2 Gy total body irradia-
tion (TBI) [14]. In this study, 86% of the patients had AML in
active relapse or MDS with more than 5% blasts in their
marrow by morphology at the time of HCT. Twenty patients
(35%) with de novo AML had primary refractory disease
(n ¼ 8) or relapsed refractory disease (n ¼ 12) at the time of
conditioning, and all 19 patients with secondary AML orMDS
had greater than 5% blasts in the marrow at the time of
conditioning. All patients achieved a complete remission as
well as 100% donor chimerism in the CD3 and CD33 com-
partments by day 28. The maximum-tolerated dose (MTD)
was estimated to be 24 Gy delivered by 131I-BC8 Ab to the
normal organ receiving the highest dose, with renal insufﬁ-
ciency and cardiopulmonary toxicities being dose-limiting
factors. This study suggested that 131I-anti-CD45 targeted
radiotherapy could be safely integrated into a reduced-
intensity conditioning regimen for older patients with
advanced myeloid malignancies. We report here a similar
strategy in younger patients (age 16 to 50 years) with
advanced AML or high-risk MDSwith the goal of deﬁning the
MTD in this age group and to create an HCT approach with
greater antitumor control and minimal added toxicities
compared with standard ablative regimens.
METHODS
Patient and Donor Selection
Patients between the age of 16 and 50 years were eligible if they had
advanced AML (deﬁned as beyond ﬁrst remission, primary refractory,
relapsed with >5% marrow blasts by morphology, or evolved from previous
myeloproliferative neoplasm or MDS), MDS with >5% blasts in the marrow,
or chronic myelomonocytic leukemia-2, and if they had HLA-matched
related or unrelated donors. Additional eligibility criteria were the same
as those in our prior study among similar patients over the age of 50 [14].
Matching for related donors involved intermediate-resolution molecular
typing for HLA-A, -B, -C, and -DQB1 and high-resolution typing for -DRB1,
according to our center’s standard practice guidelines. High-resolution
typing of HLA-A, -B, -C, and -DRB1 and intermediate-resolution typing of
DQB1 were used for allele matching of eligible unrelated donors. Both
related and unrelated donors were allowed to have a single allele mismatch
at any of the HLA-A, -B, or -C loci. DNA sequencing or oligonucleotide hy-
bridization was used to type the peripheral blood stem cell donors [15]. HCT
comorbidity indices (HCT-CI) were calculated for patients as previously
described [16]. All patients signed consent forms approved by the institu-
tional review board of the Fred Hutchinson Cancer Research Center (FHCRC).
NCI Clinical Trials Network registration: NCT00119366.
Production of Radiolabeled Antibody, Biodistribution, and Dosimetry
The radiolabeled BC8 Ab (a murine IgG1 Ab to CD45) was produced,
labeled with 131I (New England Nuclear, Boston, MA) (speciﬁc activityw8.0 Ci/mg) and tested in the Biologics Production Facility at the FHCRC as
previously described [3]. Patients were screened for human antimouse Ab
using an ELISA as previously described [14]. Thyroid uptake of free 131I was
blocked by the administration of oral Lugol’s solution (iodine/potassium
iodide solution) starting 2 days before the biodistribution dose and
continuing for 3 weeks after the therapeutic dose of 131I-BC8 Ab. A trace-
labeled infusion of 5 mCi 131I-labeled BC8 Ab was ﬁrst given to determine
the biodistribution of Ab and to estimate radiation absorbed doses to
marrow, spleen, and nontarget organs delivered per mCi of 131I, as previ-
ously described [4,14,17-19]. Methods consistent with those recommended
by the Society of Nuclear Medicine’s and Molecular Imaging’s special com-
mittee on Medical Internal Radiation Dose were used to determine the ra-
diation absorbed doses, as previously described [20].
Therapy
Regardless of the biodistribution study results, all patients were eligible
to receive a therapy dose of 131I-BC8, as the estimated radiation doses
delivered to marrow and spleen in previous studies were greater than doses
to lung, kidney, and total body, even among the few patients whose marrow
dose was slightly lower than liver dose [3,5]. The therapeutic BC8 Ab was
labeled with the amount of 131I calculated to deliver the desired dose to the
normal organ (almost always liver) estimated to receive the highest radia-
tion dose, unless that would result in an estimated marrow dose of >43 Gy,
which was similar to our previous study of older patients who underwent
transplantation for advanced myeloid malignancies [14]. Brieﬂy, patients
were isolated in lead-lined rooms until radiation exposure was  7 milli-
roentgen/hour at 1 meter (median 6, range, 2 to 11 days). FLU 30 mg/kg/day
was given intravenously (i.v.) on days4,3, andL2, followed by TBI (2 Gy;
.06 to .07 Gy/minute from a linear accelerator) and subsequent infusion of
unmanipulated, mobilized peripheral blood stem cells on day 0. Cyclo-
sporine and mycophenolate mofetil were used for graft-versus-host disease
(GVHD) prophylaxis, as previously described [14]. All patients received
prophylaxis against veno-occlusive disease with ursodiol [21].
Dose-Adjustment Schema and Statistical Analysis
The primary objective of this study was to estimate the MTD of 131I-BC8
Ab used in combinationwith FLU/2-Gy TBI. TheMTDwas deﬁned as the dose
delivered to the normal organ receiving the highest radiation exposure that
was associated with a dose-limiting toxicity (DLT) rate of 25% using the
Bearman criteria, developed speciﬁcally for HCT patients. A DLTwas deﬁned
as a Bearman grade III or grade IV regimen-related toxicity occurring up to
day 100 after HCT [22]. A 2-stage approach described by Storer et al. was
planned for dose adjustment [23]. In stage I, each successive patient received
2 Gy more radiation to the dose-limiting normal organ than the previous
patient until theﬁrst DLTwas observed. Stage II was then initiated at the next
lower dose level, treating patients in cohorts of 4. Dose escalation or de-
escalation was carried out to allow for a maximum of 20 patients enrolled
in the second stage, as previously described [14]. The ﬁrst patient received
12 Gy to the organ receiving the highest radiation absorbed dose and did not
experience a DLT. After analysis of patients older than 50 years treated with
the same regimen revealed an estimatedMTD of 24 Gy [14], the next patient
in this trial was treated at a dose of 22 Gy. Because of the high-risk features of
this patient population, we did not delay enrollment until all previously
treated patients in a cohort could be evaluated for DLT. Therefore, additional
patients could be enrolled at the current dose level and their outcome did not
affect the dose-adjustment decision, unless required for safety reasons.
Accrual, in some instances, was fairly rapid, resulting in more than 1 patient
enrolled at each dose level, despite the absence of observed DLTs.
Secondary objectives included an examination of potential efﬁcacy in the
context of a dose-ﬁnding study. For these purposes, overall survival (OS) and
relapse-free survival (RFS) were estimated according to the Kaplan-Meier
method, and relapse and NRM were summarized using cumulative inci-
dence estimates. NRM was considered a competing risk for relapse, and
relapse was treated as a competing risk for NRM.
RESULTS
Patient Characteristics
Of the sixteen patients enrolled on study, 1 patient
developed gram-negative bacteremia after dosimetry and
did not receive the therapeutic infusion of 131I-BC8 Ab.
Fifteen patients with a median age of 39 years (range, 23 to
49) and an average HCT-CI score of 2.7 (range, 0 to 5)
received a therapeutic infusion of 131I-BC8 Ab followed by
FLU, 2-Gy TBI, and allogeneic HCT. Five of these patients had
primary refractory or relapsed refractory AML (all with
circulating CD45þ blasts present at time of BC8 infusion), 9
Table 1
Patient Characteristics
Patient
No.
Age/
Gender
Disease Status at Treatment Cytogenetic
Risk
Stratiﬁcation*
HCT-CI Planned Dose
to Liver
(or Marrow)
Donor
Status
Grade
Acute
GVHD
Current Status, Days after HCT
1. 34/F AML-primary refractory Int. 4 12 Gy MUD 2 Relapse d 26; died d 42
2. 48/M AML-second remission High 0 22 Gy MUD 2 Alive and disease free: 1897 d
3. 49/M AML-relapsed refractory Int. 1 22 Gy MUD 2 Alive and disease free: 1863 d
4. 39/F AML-second remission High 5 24 Gy MRD 2 Alive and disease free: 3025 d
5. 23/M AML-second remission Unk. 5 24 Gy MUD 2 Died of cardiomyopathy on d 437
(in remission)
6. 29/M AML-second remission High 4 24 Gy MUD 2 Relapse d 1364; died d 1922
7. 43/F AML-second remission Int. 2 43 Gy MRD 2 Died of grade IV GVHD on d 544
(in remission)
8. 48/M AML-second remission Int. 5 26 Gy MRD 2 Relapse d 29; died on d 191
of fungal pneumonia
9. 48/M MDS/AML-second remission Int. 1 43 Gy MRD 2 Relapse d 39; died d 1620
10. 30/F AML-second remission Int. 1 43 Gy MRD 1 Alive and disease free: 1798 d
11. 37/M AML-second remission Int. 1 28 Gy MUD 2 Relapse d 1072; died d 1110
12. 40/F CMML-2 Int. 2 28 Gy MUD 3 Alive and disease free: 1709 d
13. 43/F MDS/AML-primary
refractory
High 3 43 Gy MRD 0 Relapse d 27; died d 307
14. 25/M AML-primary refractory High 4 28 Gy MRD 2 Relapse d 78; alive at d 1549
15. 39/M AML-primary refractory High 3 28 Gy MRD 2 Relapse d 28; died d 91
F indicates female; Int., intermediate; MUD, matched unrelated donor; M, male; Unk., unknown; MRD, matched related donor; CMML-2, chronic myelomo-
nocytic leukemia-2.
* According to Southwest Oncology Group criteria [24].
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tient had chronic myelomonocytic leukemia-2. Four patients
had high-risk, 10 had intermediate-risk, and 1 had favorable-
risk cytogenetics, according to the Southwest Oncology
Group criteria [24]. Eight patients had HLA-matched related
donors, and 7 patients had HLA-matched unrelated donors
(Table 1).Table 2
Acute GVHD in Patients Receiving 131I-BC8/FLU/TBI and HLA-Matched
Related and Unrelated Allogeneic HCT
Patient
No.
Acute GVHD
Grade
Acute GVHD
Skin Stage
Acute GVHD
Gut Stage
Acute GVHD
Liver Stage
1. 2 1 1 0
2. 2 3 1 0
3. 2 3 0 0Toxicities and GVHD
Despite premedication, grade 2 and 3 Ab-related infusion
reactions (ie, fever and chills) were observed in 8 of 15 pa-
tients; however, they resolved by the end of each infusion.
Notably, no CommonToxicity Criteria grade 4 Ab-related side
effects were observed. Hepatic veno-occlusive disease was
not observed in any of the 15 patients treated, despite
delivering an average of 21 Gy to the liver via 131I-BC8 Ab. No
patient developed grade IV GVHD during the ﬁrst 100 days
after HCT; however, 1 patient developed grade III GVHD and
12 patients developed grade II GVHD (Table 2) [25,26]. Two
patients had elevated concentrations of thyroid-stimulating
hormone in the blood by day 100 after HCT, consistent
with results from our prior study [14]. Data regarding chronic
GVHD was available for 12 of the 15 patients, because 2 pa-
tients died before day 100 and 1 patient was lost to follow-
up. Of the 12 patients with chronic GVHD data, 10 of these
patients had documented evidence of chronic GVHD, most
commonly involving the skin and mouth. Six of the patients
who developed chronic GVHD had matched unrelated do-
nors and 4 of these patients had matched related donors.4. 2 0 1 0
5. 2 3 0 0
6. 2 2 1 0
7. 2 0 1 0
8. 2 3 1 0
9. 2 3 1 0
10. 1 2 0 0
11. 2 1 1 0
12. 3 3 0 2
13. 0 0 0 0
14. 2 3 1 0
15. 2 2 1 0Biodistribution, Dosimetry, and Engraftment
Approximately 9 days after the biodistribution study,
patients received BC8 Ab labeled with the amount of 131I
activity calculated to deliver an estimated 12 to 28 Gy to the
normal organ receiving the highest dose (ie, typically the
liver). The mean absorbed dose per unit administered ac-
tivity (cGy/mCi  SD) for the 15 treated patients was 5.1  4
to the bone marrow, 3.5  1.0 to liver, 15.8  7.2 to spleen,
.5  .2 to kidney, .3  .1 to lung, and .4  .1 to the total body(Figure 1). Themean absorbed doses to the bonemarrow and
spleen were 24  15 and 76  22 Gy for patients with
recurrent AML after HCT, respectively, compared with
27  14 and 91  39 Gy for those without recurrent disease,
respectively. The 131I activity administered at each dose level
and calculated absorbed doses to marrow and spleen are
summarized in Table 3.
Despite the lack of any grade III and IV DLTs observed
among the 15 patients treated, including 7 treated at the
highest dose, the BC8 Ab was not labeled with higher
amounts of 131I that would deliver >28 Gy to any critical
normal organ because of concerns of potential damage to the
Ab avidity and function. Dosimetry showed that the planned
amount of 131I-BC8 would deliver more than 43 Gy to the
marrow in 1 of the 2 patients treated at the 26-Gy dose level
(liver) and 3 of the 7 patients treated at the 28-Gy dose level
(liver). Because of theoretical concerns for graft failure, the
radiation absorbed dose from 131I-BC8 Ab in these 4 patients
was capped at the highest dose that would deliver the
equivalent of 43 Gy to the marrow.
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Figure 1. Estimated radiation absorbed doses per millicurie of 131I adminis-
tered for all 15 patients.
Figure 2. Estimates of the probability of OS, RFS, NRM, and relapse among all
patients who received a therapeutic dose of 131I-BC8 Ab followed by TBI/FLU.
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marrow stromal damage was not observed among the 15
treated patients. Transfusion-independent platelet counts
surpassed 20,000/mL after a median of 12 days (range, 10 to
27) and sustained neutrophil counts surpassed 500/mL after a
median of 15 days (range, 13 to 22) after HCT. Chimerism
studies documented 93% donor-derived cells in the CD33þ
and CD3þ compartments of the blood by day 28 after HCT in
13 patients. One patient lacked day-28 chimerism data but
had 100% donor chimerism in both compartments by day 56.
The only patient who did not achieve93% donor chimerism
by day 28 underwent transplantation for primary refractory
AMLwith high-risk cytogenetics and relapsed on day 27 after
HCT.Overall and RFS, NRM, and Relapse
Of the 15 patients who received a therapeutic infusion of
131I-BC8 Ab, 6 patients are still alive, with amedian follow-up
of 5.0 years (range, 4.2 to 8.3 years). Median OS and RFS (the
time at which the Kaplan-Meier estimates cross 50%) of these
15 patients were 4.4 years and 1.5 years, respectively. The
estimated survival at 1 year was 73% among the 15 treated
patients (Figure 2). The estimated probabilities of relapse and
RFS at 1 year were 33% and 67%, respectively. Figure 2
summarizes the probabilities of OS, RFS, relapse, and NRM
among all 15 patients. Eight patients relapsed, 7 of whom
subsequently died. The median time to relapse among theseTable 3
131I Activity Administered, Total Absorbed Radiation Doses, and Grade 3 or 4 Regim
Dose to Liver, Gy* mCi 131Iy [MBq] Dose to
12 345 [12,765] 12.0
22 461.0  9.9 (454-468)
[17,057  366.3 (16,798-17,316)]
19.2  .
24 981.3  510.6 (598-1561)
[39,309.3  18,893.7 (22,126-57,757)]
15.3  5
26 479  80.6 (422-536)
[17,723  2982.6 (15,614-19,832)]
24.6  2
28 655.7  277.1 (332-1029)
[24,259.8  10,250.8 (12,284-38,073)]
34.0  1
MBq indicates megabecquerel.
* Protocol modiﬁed to increase starting dose to 22 Gy to organ receiving highest
the same regimen [14].
y Mean  SD (range).8 patients was 54 days (range, 26 to 1364 days). Of the 5
patients with relapsed/refractory disease and circulating
CD45þ blasts at time of HCT, 4 patients relapsed at a median
of 26.5 days (range, 26 to 78 days), with 1 patient remaining
disease free at 1863 days after HCT (Table 1). No cases of NRM
were observed in the ﬁrst year after transplantation; how-
ever, 2 patients died in remission, 1 from complications of
chronic GVHD 18months after HCTand 1 from complications
of cardiomyopathy 14 months after transplantation.DISCUSSION
Our group has previously shown encouraging results
evaluating the safety and feasibility of combining 131I-BC8 Ab
with the nonmyeloablative conditioning regimen using 2-Gy
TBI and FLU in older patients with advanced myeloid ma-
lignancies [14]. The trial described here extends the appli-
cability of 131I-anti-CD45 Ab added to FLU/2-Gy TBI as part of
allogeneic HCT conditioning to younger patients with
advance myeloid malignancies. Administration of 131I-BC8
Ab delivered an estimated average of 26 Gy to the marrow
and 82 Gy to the spleen, which were 1.2 and 3.9 times greater
than the absorbed dose delivered to the liver, respectively.
Because of a theoretical concern for stromal damage and
marrow failure, this protocol capped the maximum dose
delivered to the marrow at 43 Gy. Similar to results in our
previous trials, there was a wide range of organ-speciﬁc ra-
diation delivered by 131I-BC8 Ab, with hepatic doses ranging
from 1.5 to 4.8 cGy/mCi 131I to deliver 12 to 28 Gy to the liveren-Related Toxicities
Marrowy, Gy Dose to Spleeny, Gy DLT/No. of
Patients Treated
15.3 0/1
4 (18.9-19.5) 121.5  38.8 (94.1-148.9) 0/2
.3 (9.3-18.9) 69.82  39 (32-109.9) 0/3
6.4 (6.0-43.3) 88.6  1.2 (87.8-89.5) 0/2
3.1 (14.8-43.1) 79.5  21.5 (56.4-111.2) 0/7
dose after 24 Gy found to be the MTD in patients older than 50 treated with
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our study with older patients [14], no grade III or IV DLTs
were observed in this trial, despite targeted doses of up to
28 Gy to the liver. This suggests that younger patients may
tolerate higher hepatic radiation absorbed doses from 131I-
anti-CD45 Ab in addition to a standard reduced-intensity
conditioning regimen.
There were no cases of NRM in the ﬁrst year after trans-
plantation among the 15 patients treated, suggesting that this
transplantation-conditioning strategy may enhance the efﬁ-
cacy of reduced-intensity allogeneic HCT for patients with
AMLorMDS.Nonetheless, themost frequent causeof death in
these high-risk patients was relapse, with 47% of patients
dying from recurrent disease. In addition, 4 of the 5 patients
who underwent transplantation with active disease relapsed
within the ﬁrst 100 days after HCT. A dose limit of 43 Gy
delivered to the marrow was included in the trial, based on
results of studies using standard radiotherapy showing that
doses above45Gy results in stromaldamage that lead to long-
term local marrow hypoplasia [27]. The absence of any evi-
dence of delayed hematopoietic stem cell engraftment or
marrow failure in this trial suggests that the arbitrary limit of
43 Gy to the marrow delivered by low-dose rate radio-
immunotherapy (RIT) imposed by this protocol may have
beenunnecessarilyconservative and that furtherescalationof
the systemic dose of targeted RIT,with amuchhighermarrow
dose cap, may be advisable to further reduce the relapse rate.
Although this study treated a limited number of high-risk
patients under the age of 50, the results appear encouraging,
considering the high-risk cohort enrolled, including 33% of
patients with circulating blasts at the time of transplantation
conditioning. We, therefore, conducted a review of FHCRC
historical data among similar patients. Among 94 patients
ages 18 to 50 with AML beyond ﬁrst complete remissionwho
underwent transplantation using myeloablative regimens at
our center over the past 10 years, the estimated 1-year OS and
RFSwere64%and53%, respectively,with anestimated relapse
rate at 1 year of 32%.We note that 8 of the 15 patients treated
on our study had HCT-CI scores 3 and all patients received
HCT for AML that was beyond ﬁrst remission. Additional
retrospective data estimates the 1-year outcomes for com-
parable patients treated without radiolabeled Ab, with an
NRMof approximately 40%, a relapse rate of 35%, and an OS of
approximately 32% [28]. The NRM and survival data from this
radiolabeled Ab trial suggest that patients with high-risk
myeloid malignancies may have similar (or perhaps better)
outcomes combining RIT with FLU/2-Gy TBI compared with
those obtained using standard myeloablative regimens.
To more widely advance 131I-anti-CD45 Abebased ther-
apy, an upcoming, multi-institution, randomized phase III
trial for older patients with advanced myeloid malignancies
(http://www.actiniumpharmaceuticals.com) is in develop-
ment. Nonetheless, the optimal antigen, radiation moiety,
and delivery method to optimize an RIT regimen for HCT
remain under investigation. Previous clinical experience
demonstrated the feasibility of integrating radio-
immunoconjugates targeting CD66, CD45, or CD33 antigens
into treatment regimens for leukemias [29]. Our study
employed the therapeutic radionuclide 131I, which emits beta
particles with a .8-mm path length to CD45 antigen-positive
cells as well as surrounding antigen-negative cells in hem-
atolymphoid tissue. However, the high-energy gamma
component of 131I poses a radiation risk for staff and family,
requiring patients to be treated in radiation isolation. RIT
studies have now advanced to employ pure beta emitters,such as 90Y that delivers high energy (2.3 million electron
volts) with a relatively short half-life (2.7 days) that lacks
gamma emissions, thus eliminating the need for radiation
isolation [30-33]. To further intensify therapy and reduce
relapse, we most recently focused on preclinical studies us-
ing anti-CD45 Ab labeled with alpha emitters (213Bi, 211At) in
HCT conditioning regimens [34-36]. These alpha emitters
deposit higher energy over a much shorter distance
compared with beta emitters, providing single-cell kill while
sparing normal surrounding tissue [30]. We anticipate that
this increased cell-speciﬁc potency will provide less off-
target toxicity, resulting in an approach that decreases
relapse rates and is better tolerated. Alpha emitters may
prove particularly useful for minimal-residual disease or
extramedullary disease, as well as in the non-HCT setting, if
conjugated to select target antigens. To this end, RIT
employing the alpha emitter 225Ac conjugated to a CD33 Ab
remains under evaluation, as a single agent or in combina-
tion, for MDS and AML patients of various ages and disease
states (NCI Clinical Trials Network registration NCT01756677
and NCT00672165).
As noted in our study, there are limitations, however, to
the amount of radiation delivered by conventional RIT. In
particular, the long circulating half-life of a radiolabeled Ab
increases normal organ radiation exposure, limiting further
dose escalation. To address this issue, 1 new pretargeted
approach under investigation involves administration of the
monoclonal Ab followed by separate administration of the
radiolabeled moiety. Our pretargeted strategy capitalizes on
the well-established streptavidin-biotin afﬁnity and allows
for rapid localization of radiolabeled biotin after maximal
accumulation of streptavidin-bound Ab at target sites. Pre-
clinical studies using both beta and alpha emitters have
shown that a pretargeted strategy can deliver more than 3
times the target-speciﬁc absorbed radiation dose compared
with conventional RIT [37-39]. We have translated these
results to the clinic, where a pretargeted RIT trial is ongoing
for patients with advanced leukemia or MDS requiring HCT
(NCI Clinical Trials Network registration: NCT00988715).
Future integration of alpha emitters with a pretargeted
strategy will likely increase the potency of leukemia-speciﬁc
cytotoxicity, possibly with an improved toxicity proﬁle. We
anticipate the expansion of RIT feasibility and maximization
of its effect through the use of alpha emitters and pretargeted
technology in future studies, with the ultimate goal of
improving the tolerability and outcomes after allogeneic HCT
for patients with advanced leukemia.
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